Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Pflat In 2005: Revenue Will Be "Substantially Unchanged"

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer expects flat revenue growth during 2005 in the face of patent expirations and the poor performance of its COX-2 inhibitors

You may also be interested in...



No Merger Needed: Pfizer Efficiency Program To Generate $4 Bil. In Savings

Pfizer is launching a productivity initiative to generate $4 bil. in annual cost savings by 2008, the company announced during its New York City analyst meeting April 5

Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says

Company is predicting a return to growth in the COX-2 category once FDA completes work on new labeling. Celebrex and Bextra "will remain critical treatment options for many years to come," Pfizer tells analysts.

No Merger Needed: Pfizer Efficiency Program To Generate $4 Bil. In Savings

Pfizer is launching a productivity initiative to generate $4 bil. in annual cost savings by 2008, the company announced during its New York City analyst meeting April 5

Topics

UsernamePublicRestriction

Register

PS062141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel